Improved Pharma Enhances Drug Development with Automated Dissolution Technologies

In a significant advancement in pharmaceutical research, Improved Pharma has unveiled a new automated dissolution system designed to revolutionize drug development. This innovation allows for enhanced analytical capabilities, offering high-resolution data critical for evaluating complex drug products. Installed at their West Lafayette facility, the new system combines the Agilent 708-DS dissolution apparatus with the 850-DS autosampler, paving the way for more efficient and accurate dissolution testing.

Benefits of the New Automated System

The upgraded capabilities of Improved Pharma's dissolution system facilitate highly controlled and reproducible testing. By automating elements such as temperature control, hydrodynamics, and sampling timing, the variability introduced by operators is considerably reduced. This precision allows researchers to obtain critical insights into formulation compositions and solid-state changes that traditional methods often overlook.

"Dissolution testing serves as more than just a quality control step; it is a crucial diagnostic approach that weaves together solid-state form, formulation design, and manufacturing processes into a comprehensive evaluation," explained Steve Byrn, the Chief Scientific Officer at Improved Pharma. He emphasized that this enhancement offers clients a much clearer understanding of the various factors influencing drug release, thus aiding in achieving targeted product profiles more effectively while reducing the potential for costly delays in later development stages.

Enhancing Research and Development

The new dissolution capabilities are poised to significantly bolster efforts in formulation screening, stability studies, and process development. When combined with existing technologies such as ultra-performance liquid chromatography (UPLC) and liquid chromatography-mass spectrometry (LC–MS), this advanced system establishes a direct alignment between drug release behaviors, assay outcomes, and associated impurity profiles.

Pam Smith, Chief Operating Officer, also remarked, "This investment reflects our dedication to swift, data-driven decision-making that benefits our clients. Automation not only boosts our efficiency in sampling during extensive periods but also mitigates risks surrounding complex systems like amorphous solid dispersions, which are significantly impacted by dynamic processes that sophisticated dissolution testing can elucidate."

Looking Ahead

For detailed insights into how these advancements can aid pharmaceutical development, strengthen solid-state diagnostics, and manage lifecycle risks, industry professionals are encouraged to visit Improved Pharma's blog, where they share their vision and findings. This strategic development reaffirms Improved Pharma's position as a pioneer in the field, committed to enhancing methodologies, formulations, and processes within pharmaceutical research.

In conclusion, the introduction of automated dissolution capabilities marks a critical leap forward for Improved Pharma, allowing them to offer unparalleled support to clients in a rapidly evolving pharmaceutical landscape. The integration of this technology underscores the company's mission to lead in improvements within the industry, promising to reshape how pharmaceutical testing and development are approached altogether.